Eribulin for heavily pre-treated metastatic breast cancer patients

Table 1 Characteristics of patients and tumors in this series

	Median	Range
Age at diagnosis	47	30-73
Age at eribulin treatment	53	34-75
	Patients (n = 21)	%
Hormonal status
ER/ PgR positive	16	76.5
ER/PgR / Her2 negative	5	23.8
Grade
III	12	57.2
II	5	23.8
Unknown	4	19
Performance status
0-1	13	61.9
2-3	8	38.1
Number of metastatic sites
2	3	14.3
More than 2	18	85.7

ER: Estrogen Receptor; PgR: Progesterone Receptor; Her2: Her2/neu oncogene of the EGFR (Epidermal Growth Factor Receptor) family.